SynthesisFrontiers in medicine2025
Comparative effectiveness of ten CPMs for acute exacerbation of chronic obstructive pulmonary disease: systematic review and network meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a prevalent acute respiratory disease in China, necessitating effective treatments. Purpose: To investigate the therapeutic and safety profiles of Chinese patent medicines (CPMs) for AECOPD. Methods: Randomized controlled trials (RCTs) investigating CPMs for AECOPD were retrieved from PubMed, Cochrane Library, Embase, Web of Science, CNKI, VIP, Wanfang, and CBM. Reviewers independently conducted study selection, data extraction, and bias risk using the Cochrane RoB 2.0. The principal endpoints included total effective rate and pulmonary function parameters; secondary endpoints comprised arterial blood gas indices, inflammatory markers, and adverse events. A frequentist-based analytical strategy was utilized, with StataSE 18.0 for analysis. Results: 84 RCTs comprising 8,477 participants and 10 CPMs were included. ZCL showed the greatest improvement in total effective rate (RR 4.26, 95% CI 2.24-8.09; SUCRA 72.4%). SWLDH ranked highest for FVC (MD 0.58, 95% CI 0.29-0.87; SUCRA 94.5%) and FEV Conclusion: CPMs may improve total effective rate, pulmonary function, blood gas parameters, and inflammatory markers in AECOPD. However, these findings require confirmation by high-quality studies. Systematic review registration: [https://www.crd.york.ac.uk/PROSPERO/view/], identifier [CRD420251059887].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.